Although clinical research involving psychedelics showed
great promise over 60 years ago when it began, false information peddled by the
media and throughout popular culture framed many of these plant-based chemicals
as drugs of abuse or even as the cause of rebellions. As a result, the clinical
studies evaluating their potential for good dried up as the drugs became
tightly regulated and funding for research became increasingly scarce.
Fortunately, studies began to re-emerge around the 1990’s
and this time the potential of these substances could no longer be ignored.
Part of what is great about these unique substances is that they can be
administered in animal models, allowing us to not only gain greater insight
into their efficacy as a method of treatment, but they also help us to learn
more about the mechanisms that may be underlying these various mental/emotional
disorders.
For example, repeated administration of LSD activates
feel-good receptors in the front of our brains, which eventually leads to their
down-regulation—making us more sensitive to future feel-good moments (Buckholtz
et al., 1990). Post-mortem brain samples of people with major depression showed
an increase in these same receptors (Shelton et al., 2008), and mice
genetically engineered to have a low amount of these receptors showed a
significant decrease in anxiety-like behavior (Weisstaub et al., 2006). This research
along with many other studies suggests that LSD could really help people with
depression and anxiety disorders!
Currently, the theory is that these receptors may normally
play a role in modulating the activity of other brain structures like the amygdala
(Weisstaub et al., 2006), which is known for its function in fearful memory-associations
(this part of the brain tends to be enlarged in people with PTSD for example
(Kuo et al., 2012)), so if down-regulating these receptors can cause a decrease
in the bad mojo feelings that come from the amygdala, this could lead to some
promising avenues for treating a disorder that we still don’t really
understand.
Right now the goal of this research is to break the stigma
that these drugs currently hold so that we can finally pursue some novel (and
promising!) approaches to the many mental/emotional disorders that are
currently plaguing our society. Also by deepening our understanding of the
underlying mechanisms of these disorders, we can seek to develop other effective
treatments that have less psychoactive symptoms, potentially allowing us to
treat even more people.
References:
Buckholtz NS, Zhou DF, Freedman DX, Potter WZ. (1990) Lysergic
acid diethylamide (LSD) administration selectively downregulates serotonin2
receptors in rat brain. Journal of Neuropsychopharmacology.
137-148
Kuo JR, Kaloupek DG, Woodward SH. (2012).
Amygdala Volume in Combat-Exposed Veterans With and Without Posttraumatic
Stress Disorder: A Cross-sectional Study. Archive of General
Psychiatry. 69(10),1080–1086. doi:10.1001/archgenpsychiatry.2012.73
Shelton, R.C., Sanders-Bush, E.,
Manier, D.H., & Lewis, D.A. (2008). Elevated 5-HT 2A receptors in
postmortem prefrontal cortex in major depression is associated with reduced
activity of protein kinase, A. Journal of
Neuroscience. 158,1406-1415
Weisstaub, N.V. et al. (2006). Cortical 5-HT2A receptor
signaling modulates anxiety-like behaviors in mice. Journal of Science. 313, 536-540